Effect of chronic treatment of carvedilol on oxidative stress in an intracerebroventricular streptozotocin induced model of dementia in rats

Journal of Pharmacy and Pharmacology

Volumn 61, Issue 12, 2009, Pages 1665-1672

  Prakash, Atish Kumar ^a   Kumar, Anil ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

Carvedilol; Dementia; Neuroprotection; Oxidative stress; Streptozotocin

Indexed keywords

ACETYLCHOLINESTERASE; CARVEDILOL; CATALASE; GLUTATHIONE; MALONALDEHYDE; NITRATE; NITRITE; PROTEIN; STREPTOZOCIN; SUPEROXIDE DISMUTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN LATERAL VENTRICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DEGENERATIVE DISEASE; DEMENTIA; DRUG EFFECT; ENZYME ACTIVITY; LIPID PEROXIDATION; LOCOMOTION; LONG TERM CARE; MALE; MAZE TEST; MEMORY CONSOLIDATION; MEMORY DISORDER; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; RAT; TASK PERFORMANCE; TREATMENT DURATION;

ACETYLCHOLINESTERASE; ANIMALS; ANTIOXIDANTS; BEHAVIOR, ANIMAL; BRAIN; CARBAZOLES; CATALASE; DEMENTIA; DRUG ADMINISTRATION ROUTES; DRUG ADMINISTRATION SCHEDULE; GLUTATHIONE; MALE; MALONDIALDEHYDE; MAZE LEARNING; MODELS, ANIMAL; NITRITES; OXIDATIVE STRESS; PROPANOLAMINES; RATS; RATS, WISTAR; STREPTOZOCIN; SUPEROXIDE DISMUTASE;

EID: 75749128269     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp/61.12.0012     Document Type: Article

References (49)

1. Mirra SS et al. The consortium to establish a registry for Alzheimer's disease. Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991; 41: 479-486.
2. Calabrese V et al. Nitrosative stress, cellular stress response, and thiol homeostasis in patients with Alzheimer's disease. Antioxid Redox Signal 2006; 8: 1975-1986.
3. Olanow CW. A radical hypothesis for neurodegeneration. Trends Neurosci 1993; 16: 439-444.
4. Medeiros R et al. Connecting TNF-a signaling pathway to iNOS expression in a mouse model of Alzheimer's disease: relevance for the behavioral and synaptic deficits induced by amyloid-β protein. J Neurosci 2007; 27: 5394-5404.
5. Stuchbury G, Münch G. Alzheimer's associated inflammation, potential drug targets and future therapies. J Neural Transm 2005; 112: 429-453.
6. Mandelkow EM et al. Clogging of axons by tau, inhibition of axonal traffic and starvation of synapses. Neurobiol Aging 2003; 24: 1079-1085.
7. Araujo JA et al. Improvement of short-term memory performance in aged beagles by a nutraceutical supplement containing phosphatidylserine, Ginkgo biloba, vitamin E, and pyridoxine. Can Vet J 2008; 49: 379-385.
8. Head E. Oxidative damage and cognitive dysfunction: antioxidant treatments to promote healthy brain aging. Neurochem Res 2009; 34: 670-678.
9. Savitz SI et al. The novel β-blocker, carvedilol, provides neuroprotection in transient focal stroke. J Cereb Blood Flow Metab 2000; 20: 1197-1204.
10. Yaoita H et al. Differential effects of carvedilol, metoprolol and propranolol on left ventricular remodeling after coronary stenosis or after permanent coronary occlusion in rats. Circulation 2002; 105: 975-980.
11. Abreu RMV et al. Effects of carvedilol and its analog BM-910228 on mitochondrial function and oxidative stress. J Pharmacol Exp Ther 2000; 295: 1022-1030.
12. Lysko PG et al. Neuroprotective effects of carvedilol, a new antihypertensive agent, in cultured rat cerebellar neurons and in gerbil global brain ischemia. Stroke 1992; 23: 1630-1636.
13. Naidu PS et al. Carvedilol attenuates neuroleptic-induced orofacial dyskinesia: possible antioxidant mechanisms. Br J Pharmacol 2002; 136: 193-200.
14. Ma XL et al. Carvedilol, a new beta adrenoceptor blocker and free radical scavenger attenuates myocardial ischemia reperfusion injury in hypercholesterolemic rabbits. J Pharmacol Exp Ther 1996; 277: 128-136.
15. Padi SS, Chopra K. Salvage of cyclosporine A-induced oxidative stress and renal dysfunction by carvedilol. Nephron 2002; 92: 685-692.
16. Oettl K et al. Radical-scavenging and iron-chelating properties of carvedilol, an antihypertensive drug with antioxidative activity. Biochem Pharmacol 2001; 62: 241-248.
17. Suzuki Y et al. Antioxidant properties of carvedilol: inhibition of lipid peroxidation, protein oxidation and superoxide generation. Neurol Res 2003; 25: 749-753.
18. Yue TL et al. Carvedilol, a new antihypertensive drug with unique antioxidant activity: potential role in cerebroprotection. Ann NY Acad Sci 1994; 738: 230-242.
19. Howlett DR et al. Common structural features determine the effectiveness of carvedilol, daunomycin and rolitetracycline as inhibitors of Alzheimer β-amyloid fibril formation. Biochem J 1999; 343: 419-423.
20. Sharma M, Gupta YK. Intracerebroventricular injection of streptozotocin in rats produces both oxidative stress in the brain and cognitive impairment. Life Sci 2001; 68: 1021-1029.
21. Lannert H, Hoyer S. Intracerebroventricular administration of streptozotocin causes long-term diminutions in learning and memory abilities and in cerebral energy metabolism in adult rats. Behav Neurosci 1998; 112: 1199-1208.
22. Prickaerts J et al. Spatial discrimination learning and choline acetyltransferase activity in streptozotocin-treated rats: effects of chronic treatment with acetyl-L-carnitine. Brain Res 1995; 674: 142-146.
23. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates, 2nd edn. San Diego: Academic Press, 1986.
24. Kumar A et al. Differential effects of cyclooxygenase inhibitors on intracerebroventricular colchicine-induced dysfunction and oxidative stress in rats. Eur J Pharmacol 2006; 551: 58-66.
25. Reddy DS, Kulkarni SK. Possible role of nitric oxide in the nootropic and antiamnesic effects of neurosteroids on aging and dizocilpine-induced learning impairment. Brain Res 1998; 799: 215-229.
26. Wills ED. Mechanism of lipid peroxide formation in animal tissues. Biochem J 1966; 99: 667-676.
27. Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys 1959; 82: 48 670-48 677.
28. Green LC et al. Analysis of nitrate, nitrite and (15 N) nitrate in biological fluids. J Biol Chem 1982; 193: 265-275.
29. Kono Y. Generation of superoxide radical during auto-oxidation of hydroxylamine and an assay for superoxide dismutase. Arch Biochem Biophys 1978; 186: 189-195.
30. Luck H. Catalase. In: Bergmeyer HU, ed. Methods of Enzymatic Analysis. New York: Academic Press, 1978: 885-893.
31. Ellman GL et al. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961; 7: 88-95.
32. Gornall AG et al. Determination of serum proteins by means of Biuret reaction. J Biol Chem 1949; 177: 751-766.
33. Saxena G et al. Effect of donepezil and tacrine on oxidative stress in intracerebral streptozotocin-induced model of dementia in mice. Eur J Pharmacol 2008; 58: 1283-1289.
34. Sharma M, Gupta YK. Chronic treatment with trans resveratrol prevents intracerebroventricular streptozotocin induced cognitive impairment and oxidative stress in rats. Life Sci 2002; 71: 2489-2498.
35. Yue TL et al. Carvedilol, a new vasodilator and β-adrenoceptor antagonist, inhibits oxygen-radical induced lipid peroxidation in swine ventricular membranes. Pharmacol Res Commun 1992; 1: 27-35.
36. Yue TL et al. Carvedilol, a new vasodilator and β-adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther 1992; 263: 92-98.
37. Macickova T et al. Influence of carvedilol on superoxide generation and enzyme release from stimulated human neutrophils. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2005; 149: 389-392.
38. Ruffolo RR et al. Carvedilol: a novel cardiovascular drug with multiple actions. Cardiovasc Drug Rev 2007; 10: 127-157.
39. Feuerstein GZ et al. Carvedilol update IV: prevention of oxidative stress, cardiac remodeling and progression of congestive heart failure. Drugs Today 1997; 33: 453-457.
40. Beal MF. Ageing, energy and oxidative stress in neurodegenerative disease. Ann Neurol 1995; 38: 357-366.
41. Bondy CS. The relation of oxidative stress and hyperexcitation to neurological disease. Proc Soc Exp Biol Med 1995; 208: 337-345.
42. Fass U et al. Differential vulnerability of primary cultured neurons to nitric oxide excess. Neuroreport 2003; 11: 931-936.
43. Dawson JR et al. Excitotoxins, aging and environmental neurotoxins: implications for understanding human neurodegenerative diseases. Toxicol Appl Pharmacol 1995; 134: 157-167.
44. Yoshioka T et al. Anti-NO action of carvedilol in cell-free system and in vascular endothelial cells. Br J Pharmacol 2000; 129: 1530-1535.
45. Tuppo EE, Arias HR. The role of inflammation in Alzheimer's disease. Int J Biochem Cell Biol 2005; 37: 289-305.
46. Yuan Z et al. Cardioprotective effects of carvedilol on acute autoimmune myocarditis: anti-inflammatory effects associated with antioxidant property. Am J Physiol Heart Circ Physiol 2004; 286: H83-H90.
47. Barone FC, Feuerstein GZ. Inflammatory mediators and stroke: new opportunities for novel therapeutics. J Cereb Blood Flow Metab 1999; 19: 819-834.
48. Weinstock M et al. Neuroprotective effects of novel cholinesterase inhibitors derived from rasagiline as potential anti-Alzheimer drugs. Ann N Y Acad Sci 2001; 939: 148-161.
49. Blokland A, Jolles J. Behavioral and biochemical effects of an ICV injection of streptozotocin in old Lewis rats. Pharmacol Biochem Behav 1994; 47: 833-837.